Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Study findings suggest people with chronic liver disease should be prioritized for booster shots.
Herpes, HIV, Epstein-Barr and other viruses hang around, causing potential long-term health woes. Should long COVID surprise us?
Plus: Over 10 prevention services related to hepatitis, HIV and sexually transmitted infections covered by the Affordable Care Act.
Insurers should allow co-pay assistance to count as out-of-pocket spending, claims HHS lawsuit by HIV, hepatitis and diabetes advocates.
The current leading suspect is an adenovirus, but much more remains to be learned.
Testing advances made during the COVID-19 pandemic may lead to “test and treat” approaches for hepatitis C. But there’s a holdup.
COVID-19 had an “immense impact” on HIV, hepatitis and STI screening, prevention and care.
HCV treatment initiation dropped by 31% from March to April 2020 and remained low throughout the year.
The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.
Disruptions in access to treatment and harm reduction services could set back effort to eliminate hep C in the U.S.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Low-barrier care and access to multiple services in one place can improve outcomes for people experiencing homelessness or unstable housing.
The early cancer is detected, the easier it is to treat.
Mobile clinics could be innovative strategy for expanding access to care and providing uninterrupted treatment for people who inject drugs.
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
Health officials remain concerned about HIV and hepatitis C transmissions during COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.